Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Immuntherapeutische Verfahren in der Therapie gastrointestinaler Tumore

Andreas Block; Innere Medizin, Hämatologie und internistische Onkologie, Gastroenterologie Universitätsklinikum Hamburg-Eppendorf (S. 10–15)

  1.  
    1.  Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26), 2517–2526. doi:10.1056/NEJMoa1104621
  2. Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015, 372(21), 2018–2028. doi:10.1056/NEJMoa1501824
  3. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015, 373(1), 23-34. doi:10.1056/NEJMoa1504030
  4. Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015, 372(21), 2006–2017. doi:10.1056/NEJMoa1414428
  5. Moehler, M., Delic, M., Goepfert, K., Aust, D., Grabsch, H. I., Halama, N. et al. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. Eur J Cancer 2016, 59, 160–170. doi:10.1016/j.ejca.2016.02.020
  6. Sun, X., Suo, J., & Yan, J. Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol 2016, 22(28), 6362–6372. doi:10.3748/wjg.v22.i28.6362
  7. Gao, Q., Wang, X. Y., Qiu, S. J., Yamato, I., Sho, M., Nakajima, Y. et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009, 15(3), 971–979. doi:10.1158/1078-0432.CCR-08-1608
  8. Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13(7), 2151–2157. doi:10.1158/1078-0432.CCR-06-2746
  9. Chatterjee, S., Behnam Azad, B., & Nimmagadda, S. The intricate role of CXCR4 in cancer. Adv Cancer Res 2014, 124, 31–82. doi:10.1016/B978-0-12-411638-2.00002-1
  10. Coussens, L. M., & Werb, Z. Inflammation and cancer. Nature 2002, 420(6917), 860–867. doi:10.1038/nature01322
  11. Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N. et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005, 202(8), 1075–1085. doi:10.1084/jem.20051511
  12. Waghray, M., Yalamanchili, M., di Magliano, M. P., & Simeone, D. M. Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroenterol 2013, 29(5), 537–543. doi:10.1097/MOG.0b013e328363affe
  13. Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. The pancreas cancer microenvironment. Clin Cancer Res 2012, 18(16), 4266–4276. doi:10.1158/1078-0432.CCR-11-3114
  14. Cancer Genome Atlas Research, N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513(7517), 202–209. doi:10.1038/nature13480
  15. Fearon, E. R., & Carethers, J. M. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology 2015, 148(1), 10–13. doi:10.1053/j.gastro.2014.11.024
  16. Dienstmann, R., Salazar, R., & Tabernero, J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 2015, 33(16), 1787–1796. doi:10.1200/JCO.2014.60.0213
  17. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V. et al. Signatures of mutational processes in human cancer. Nature 2013, 500(7463), 415–421. doi:10.1038/nature12477
  18. McGranahan, N., Furness, A. J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016, 351(6280), 1463–1469. doi:10.1126/science.aaf1490
  19. Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015, 350(6257), 207–211. doi:10.1126/science.aad0095
  20. Xiao, Y., & Freeman, G. J.  The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 2015, 5(1), 16–18. doi:10.1158/2159-8290.CD-14-1397
  21. Galon, J., Fox, B. A., Bifulco, C. B., Masucci, G., Rau, T., Botti, G. et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med 2016, 14, 273. doi:10.1186/s12967-016-1029-z
  22. Sharma, P., & Allison, J. P. The future of immune checkpoint therapy. Science 2015a, 348(6230), 56–61. doi:10.1126/science.aaa8172
  23. Sharma, P., & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015b, 161(2), 205–214. doi:10.1016/j.cell.2015.03.030
  24. Barbee, M. S., Ogunniyi, A., Horvat, T. Z., & Dang, T. O. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015, 49(8), 907–937. doi:10.1177/1060028015586218
  25. Qing, Y., Li, Q., Ren, T., Xia, W., Peng, Y., Liu, G. L. et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther 2015, 9, 901–909. doi:10.2147/DDDT.S75152
  26. Moehler, M. H., Kim, Y. H., Tan, I. B., Balogh, A., Sanchez, T. K., & Bang, Y. J. Sequential ipilimumab (Ipi) versus best supportive care (BSC) following first-line chemotherapy (Ctx) in patients (pts) with unresectable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer: A randomized, open-label, two-arm, phase II trial (CA184-162) of immunotherapy as a maintenance concept. J Clin Oncol 2013, 31(TPS4151)
  27. Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016, 17(6), 717–726. doi:10.1016/S1470-2045(16)00175-3
  28. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015, 372(26), 2509–2520. doi:10.1056/NEJMoa1500596
  29. Chung, K. Y., Gore, I., Fong, L., Venook, A., Beck, S. B., Dorazio, P. et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol 2010, 28(21), 3485–3490. doi:10.1200/JCO.2010.28.3994
  30. Sangro, B., Gomez-Martin, C., de la Mata, M., Inarrairaegui, M., Garralda, E., Barrera, P. et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013, 59(1), 81–88. doi:10.1016/j.jhep.2013.02.022
  31. Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003, 100(14), 8372–8377. doi:10.1073/pnas.1533209100
  32. Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742), 687–697. doi:10.1016/S0140-6736(10)61121-X
  33. Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K. Y., Slack, R. et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005, 23(4), 720–731. doi:10.1200/JCO.2005.10.206
  34. Morse, M. A., Niedzwiecki, D., Marshall, J. L., Garrett, C., Chang, D. Z., Aklilu, M. et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013, 258(6), 879–886. doi:10.1097/SLA.0b013e318292919e
  35. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001, 98(15), 8809–8814. doi:10.1073/pnas.141226398
  36. Nair, S. K., Hull, S., Coleman, D., Gilboa, E., Lyerly, H. K., & Morse, M. A. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999, 82(1), 121–124. 
  37. Uyl-de Groot, C. A., Vermorken, J. B., Hanna, M. G., Jr., Verboom, P., Groot, M. T., Bonsel, G. J. et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005, 23(17–18), 2379–2387. doi:10.1016/j.vaccine.2005.01.015
  38. Dillman, R. O.. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccin Immunother 2016, 0. doi:10.1080/21645515.2016.1244149
  39. Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y. C., Dudley, M. E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344(6184), 641–645. doi:10.1126/science.1251102

Neue Biomarker und Perspektiven zielgerichteter Therapie von Kopf-Hals-Tumoren

Mareike Tometten und Tim H. Brümmendorf; Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Uniklinik der RWTH Aachen (S. 16–21)

  1. Humans, I.W.G.o.t.E.o.C.R.t., Human Papillomaviruses. Lyon (FR): International Agency for Research on Cancer, 2007; No. 90
  2. Rampias, T., et al., E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst, 2009; 101(6): p. 412–23
  3. Ragin, C.C. and E. Taioli, Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer, 2007; 121(8): p. 1813–20
  4. Fakhry, C., et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst, 2008; 100(4): p. 261–9
  5. Goon, P.K., et al., HPV & head and neck cancer: a descriptive update. Head Neck Oncol, 2009; 1: p. 36.
  6. Ang, K.K., et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med, 2010; 363(1): p. 24–35
  7. Chaturvedi, A.K., et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol, 2011; 29(32): p. 4294–301
  8. Gillison, M.L., et al., Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol, 2015; 33(29): p. 3235–42
  9. Mehanna, H., et al., Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck, 2013; 35(5): p. 747–55
  10. Heck, J.E., et al., Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol, 2010; 39(1): p. 166–81
  11. Schmeler, K.M. and E.M. Sturgis, Expanding the benefits of HPV vaccination to boys and men. Lancet, 2016. 387(10030): p. 1798–9
  12. Huang, S.H., et al., Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol, 2013; 49(1): p. 79–85
  13. Muller, S., et al., HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases? Head Neck Pathol, 2012. 6(3): p. 336–44
  14. Fakhry, C., et al., Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol, 2014; 32(30): p. 3365–73
  15. Huang, S.H., et al., Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol, 2015. 33(8): p. 836–45
  16. O'Sullivan, B., et al., Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol, 2016; 17(4): p. 440–51
  17. Schache, A.G., et al., Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res, 2011. 17(19): p. 6262–71
  18. Holzinger, D., et al., Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res, 2012; 72(19): p. 4993–5003
  19. Quabius, E.S., et al., Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany. Int J Oncol, 2015; 46(1): p. 414–22
  20. Klussmann, J.P., et al., Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol, 2003; 162(3): p. 747–53
  21. Bhatia, A. and B. Burtness, Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. J Clin Oncol, 2015; 33(29): p. 3243–50
  22. Bonner, J.A., et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 2006; 354(6): p. 567–78
  23. Rosenthal, D.I., et al., Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol, 2016 34(12): p. 1300–8
  24. Cmelak, A., et al. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). J Clin Oncol 2014; 32:5s(suppl; abstr LBA6006)
  25. Argiris, A., et al., Head and neck cancer. Lancet, 2008; 371(9625): p. 1695–709
  26. Cohen, E.E., Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol, 2006; 24(17): p. 2659–65
  27. Chung, C.H., et al., Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2011; 81(2): p. 331–8
  28. Dassonville, O., et al., Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol, 1993; 11(10): p. 1873–8
  29. Clement, P.M., et al., Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol, 2016; 27(8): p. 1585–93
  30. Specenier, P. and J. Vermorken, Afatinib in squamous cell carcinoma of the head and neck. Expert Opin Pharmacother, 2016. 17(9): p. 1295–301
  31. Stewart, J.S., et al., Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol, 2009; 27(11): p. 1864–71
  32. Soulieres, D., et al., Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 2004; 22(1): p. 77–85
  33. de Souza, J.A., et al., A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res, 2012; 18(8): p. 2336–43
  34. Weiss, J.M., et al., Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer, 2016; 122(15): p. 2350–5
  35. Lui, V.W., et al., Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov, 2013; 3(7): p. 761–9
  36. Vander Broek, R., et al., The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. Oral Dis, 2015; 21(7): p. 815–25
  37. The Cancer Genome Atlas, N., Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 2015; 517(7536): p. 576–582
  38. Grunwald, V., et al., TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Ann Oncol, 2015; 26(3): p. 561–7
  39. Soulieres, D., A Phase II, Placebo-controlled Study of Buparlisib (BKM120) Plus Paclitaxel in Patients With Platinum-pretreated, Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). J Clin Oncol 2016; 34(suppl; abstr 6008)

UPDATE

Das frühinvasive Urothelkarzinom – von Asymptomatik bis Zystektomie (S. 36–41) WolfgangOtto1,2, Maximilian Burger2, Arnulf Stenzl3, Georgios Gakis3

1Urologische Praxis Dr. Raab, Abensberg
2Klinik für Urologie der Universität Regensburg
3Universitätsklinik für Urologie der Eberhard-Karls-UniversitätTübingen

  1. Jichlinski P, Leisinger HJ. Fluorescence Cystoscopy in the Management of Bladder Cancer: A Help for the Urologist! Urol Int 2005; 74: 97–101
  2. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003 Jan; 169(1):96–100; discussion 100
  3. Kiragu D, Cifu AS. Evaluation of Patients With Asymptomatic Microhematuria. JAMA. 2015 Nov 3; 314(17):1865–6
  4. Purysko AS, Leão Filho HM, Herts BR.: Radiologic imaging of patients with bladder cancer. Semin Oncol. 2012 Oct; 39(5):543–58
  5. Kausch von Schmeling I. Diagnostik und Therapie des nicht muskelinvasiven Harnblasenkarzinoms- State of the art, Aktuell Urol 2010; 41: 307–315
  6. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016 Jun 17. pii: S0302-2838(16)30249-4
  7. Denzinger S, Rößler W, Otto W. Photodynamische Diagnostik des Harnblasenkarzinoms. Deutsche medizinische Wochenschrift 2007; 132:1–4 
  8. Otto W. Geschichtliche Entwicklung der Endoskopie. in: Otto W, Denzinger S: Theorie und Praxis der urologischen Endoskopie, S. 11–27. Forum; Regensburg, 2008
  9. Kriegmair M, Stepp H, Steinbach P, Lumper W, Ehsan A, Stepp HG, Rick K, Knüchel R, Baumgartner R, Hofstetter A. Fluorescence cystoscopy following intravesical instillation of 5-aminolevulinic acid: a new procedure with high sensitivity for detection of hardly visible urothelial neoplasias. Urol Int. 1995; 55(4):190–6
  10. Otto W, Burger M, Fritsche HM, Rössler W, Wieland WF, Denzinger S. The enlightenment of bladder cancer treatment: origin and progress of photodynamic diagnosis. Future Oncol. 2011 Sep; 7(9):1057-66. doi: 10.2217/fon.11.91
  11. Otto W, Burger M, Fritsche HM, Blana A, Roessler W, Knuechel R, Wieland WF, Denzinger S. Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results? Clin. Med. Oncol. 3, 53–58
  12. Gakis G, Ngamsri T, Rausch S, Mischinger J, Todenhöfer T, Schwentner C, Schmid MA, Hassan FA, Renninger M, Stenzl A. Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. World J Urol. 2015 Oct; 33(10):1429–37
  13. Naito S, Algaba F, Babjuk M, Bryan RT, Sun YH, Valiquette L, de la Rosette J; CROES Narrow Band Imaging Global Study Group. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. Eur Urol. 2016 Apr 22. pii: S0302-2838(16)30031-8
  14. Comperat E, Varinot J. Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 WHO classification. Histopathology. 2016 doi:10.1111/his.13025
  15. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar; 49(3):466-5; discussion 475–7
  16. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008 Apr, 53(4): 709–19 
  17. Maarouf AM, Khalil S, Salem EA, El Adl M, Nawar N, Zaiton F. Bladder preservation multimodality therapy as an alternatvie to radical cystectomy for treatment of muscle invasive bladder cancer. BJU Int. 2011 May; 107(10):1605–10
  18. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. European urology. 2014; 65 (4):778–792
  19. Gakis G, Schwentner C, Todenhofer T, Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU international 2012; 110 (2):233–237
  20. Gakis G, Todenhofer T, Braun M, Fend F, Stenzl A, Perner S. Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scandinavian journal of urology 2015; 49 (5):382–387
  21. Sternberg IA, Keren Paz GE, Chen LY, Herr HW, Dalbagni G. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection. BJU international 2013; 112(1):54–59
  22. Gakis G, Witjes JA, Comperat E, Cowan NC, De Santis M, Lebret T, Ribal MJ, Sherif AM, European Association of Urology. EAU guidelines on primary urethral carcinoma. European urology 2014; 64 (5):823–830
  23. Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. European urology 2013; 61(5):1039–1047
  24. Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU international 2013; 111(8):1215–1221
  25. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol. 2008 Jan; 53(1):146–52
  26. Gschwend JE, et al. Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02). J Clin Oncol 2016 (suppl;abstr 4503)
  27. Shiozawa T, Huebner M, Hirt B, Wallwiener D, Reisenauer C. Nerve-preserving sacrocolpopexy: anatomical study and surgical approach. European journal of obstetrics, gynecology, and reproductive biology 2010; 152(1):103–107
  28. Gakis G, Stenzl A. Considerations for orthotopic diversions in women. Current opinion in urology 2015; 25(6):550–554
  29. Fahmy O, Asri K, Schwentner C, Stenzl A, Gakis G. Current status of robotic assisted radical cystectomy with intracorporeal ileal neobladder for bladder cancer. Journal of surgical oncology 2015; 112(4):427–429
  30. Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, Hartmann A, Bertz S. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2011; 107(3):404–8
  31. May M, Brookman-Amissah S, Roigas J, Hartmann A, Störkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, Gunia S. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. 2010 May; 57(5):850–8
  32. Denzinger S, Bertz S, Otto W, Wieland WF, Stoehr R, Hofstaedter F, Hartmann A.  Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology. 2011 Oct; 59(4):722–32
  33. Denzinger S, Burger M, Fritsche HM, Bertz S, Hofstädter F, Wieland WF, Hartmann A, Otto W. Prognostic value of histopathological tumor growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder. Scand J Urol Nephrol 2009; 43(4):282–87 

PHARMAFORUM - Hodgkin-Lymphom

Brentuximab Vedotin als Bridging-Option zur Stammzelltransplantation (S. 43)

  1. Walewski J et al. ISHL10 2016, Abstract #
  2. Younes A et al. J Clin Oncol 2012; 30: 2183–8
  3. Moskowitz CH et al., Lancet 2015; 385: 1853–62